29. Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B, Hunziker W, et al. (2007) Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs 185: 61–65. 30. Nelson WJ, Nusse R (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483–1487. 31. Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signaling. Cell 103: 311–320. 32. Kikuchi A (2000) Regulation of beta-catenin signaling in the Wnt pathway. Biochemical and biophysical research communications 268: 243–248. 33. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, et al. (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proceedings of the National Academy of Sciences of the United States of America 96: 1603–1608. 34. Chen Y, Shi L, Zhang L, Li R, Liang J, et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283: 17969–17978. 35. Zorn AM, Barish GD, Williams BO, Lavender P, Klymkowsky MW, et al. (1999) Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Molecular cell 4: 487–498. 36. Zhang C, Basta T, Jensen ED, Klymkowsky MW (2003) The beta-catenin/ VegT-regulated early zygotic gene Xnr5 is a direct target of SOX3 regulation. Development 130: 5609–5624. 37. Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 39 kinase/AKT pathways. Oncogene 24: 7443–7454. 38. Jia X, Li X, Xu Y, Zhang S, Mou W, et al. (2011) SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 3: 230–238. 39. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, et al. (2011) Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. British journal of cancer 104: 1410–1417. SOX2 in Mesenchymal-Epithelial Transition 40. Burbridge TJ, Wang Y, Volz AJ, Peschansky VJ, Lisann L, et al. (2008) Postnatal analysis of the effect of embryonic knockdown and overexpression of candidate dyslexia susceptibility gene homolog Dcdc2 in the rat. Neuroscience 152: 723– 733. 41. Subbarayan V, Mark M, Messadeq N, Rustin P, Chambon P, et al. (2000) RXRalpha overexpression in cardiomyocytes causes dilated cardiomyopathy but fails to rescue myocardial hypoplasia in RXRalpha-null fetuses. J Clin Invest 105: 387–394. 42. Savore C, Zhang C, Muir C, Liu R, Wyrwa J, et al. (2005) Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis 22: 377–390. 43. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, et al. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84–89. 44. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76–83. 45. Hajra KM, Chen DY, Fearon ER (2002) The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62: 1613–1618. 46. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9–34. 47. Wiese AH, Auer J, Lassmann S, Nahrig J, Rosenberg R, et al. (2007) Identification of gene signatures for invasive colorectal tumor cells. Cancer detection and prevention 31: 282–295. 48. Park KS, Kim SJ, Kim KH, Kim JC (2011) Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. Journal of gastroenterology and hepatology 26: 391–397. 49. Leibovitz A, Stinson JC, McCombs WB 3rd, McCoy CE, Mazur KC, et al. (1976) Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562–4569. PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e41335